Protalix Q1 FY26 swings to net income of $18.32 million; revenue more than doubled to $33.75 million

Protalix Biotherapeutics, Inc.

Protalix Biotherapeutics, Inc.

PLX

0.00
  • Protalix BioTherapeutics swung to net income of USD 18.32 million, or USD 0.23 per share, from a net loss of USD 3.62 million, or USD (0.05) per share.
  • Revenue climbed to USD 33.75 million from USD 10.11 million, driven by USD 26.33 million in license and R&D services revenue that included a USD 25 million milestone from Chiesi tied to European Commission approval of Elfabrio’s 2 mg/kg every-4-weeks dosing.
  • Revenue from selling goods fell to USD 7.42 million from USD 10 million due to a timing shift in Pfizer purchases, partially offset by USD 3.5 million in sales to Chiesi.
  • R&D expenses rose 56% to USD 5.43 million as the Phase 2 RELEASE trial of PRX-115 advanced; cash, cash equivalents, and short-term bank deposits totaled USD 51.1 million at March 31.
  • Full-year 2026 revenue guidance was reaffirmed at USD 78 million-USD 83 million, including the USD 25 million milestone.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protalix BioTherapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202605130650PR_NEWS_USPR_____IO57201) on May 13, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.